C.L. van der Wilt

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers

Paul Noordhuis, U. Holwerda, C.L. van der Wilt et al. · Annals of Oncology · 2004 · 257 citations · Full text

Oncogenic Agent, Synthase Inhibition, Molecular Biology +6

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.

Godefridus J. Peters, C.L. van der Wilt, C.J. van Groeningen et al. · Journal of Clinical Oncology · 1994 · 195 citations

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

Judith R. Kroep, Willem J.P Loves, C.L. van der Wilt et al. · PubMed · 2002 · 191 citations

Vivo Gemcitabine Sensitivity, Oncology, Oncogenic Agent +15

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

Andries M. Bergman, Herbert M. Pinedo, Iannis Talianidis et al. · British Journal of Cancer · 2003 · 166 citations · Full text

Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.

Baukelien van Triest, Herbert M. Pinedo, Yvette van Hensbergen et al. · PubMed · 1999 · 145 citations

Pathology, Thymidylate Synthase, Pharmacotherapy +16